China Money Network
Login
Join

Adlai Nortye Signs China Licensing Deal for AN9025 Cancer Therapy

  • December 29, 2025 — 19:35 CST

This Data Is Locked!

This area is available only to Subscribers.

Adlai Nortye Ltd. and ASK Pharm have officially entered an exclusive licensing agreement for the pan-RAS (ON) inhibitor AN9025. The deal provides ASK Pharm sole... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: